A retrospective study of patients’ out-of-pocket costs for granulocyte colony-stimulating factors

Financial Hardship: A Consequence of Survivorship?

(2012) Cathy J. Bradley   JOURNAL OF CLINICAL ONCOLOGY

Comparative Effectiveness of Filgrastim, Pegfilgrastim, and Sargramostim as Prophylaxis Against Hospitalization for Neutropenic Complications in Patients With Cancer Receiving Chemotherapy

(2011) Derek Weycker et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

National Estimates of Out-of-Pocket Health Care Expenditure Burdens Among Nonelderly Adults With Cancer: 2001 to 2008

(2011) Didem S.M. Bernard et al.   JOURNAL OF CLINICAL ONCOLOGY

The Climbing Costs of Cancer Care

(2011) N. MacReady   JNCI-Journal of the National Cancer Institute

Patient and Plan Characteristics Affecting Abandonment of Oral Oncolytic Prescriptions

(2011) Sonya Blesser Streeter et al.   Journal of Oncology Practice

A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy

(2010) J. Randolph Hecht et al.   Clinical Colorectal Cancer

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study

(2010) Hiangkiat Tan et al.   CURRENT MEDICAL RESEARCH AND OPINION

2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

(2010) M.S. Aapro et al.   EUROPEAN JOURNAL OF CANCER

The out of pocket cost of breast cancer survivors: a review

(2010) Maria Pisu et al.   Journal of Cancer Survivorship

Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: A retrospective cohort study

(2009) Derek Weycker et al.   CLINICAL THERAPEUTICS

Economic implications of using pegfilgrastim rather than conventional G-CSF to prevent neutropenia during small-cell lung cancer chemotherapy

(2009) P. Tan Sean et al.   CURRENT MEDICAL RESEARCH AND OPINION

Pegfilgrastim   ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study

(2007) G. von Minckwitz et al.   ANNALS OF ONCOLOGY